Company: BDRX
Filing Date: 2025-06-27
Form Type: 424B3
Source: 0001214659-25-009732
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-27
Form: 424B3
Chunk 2
---
 deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of June 2025 is:

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: June 27, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:--------------------|:----------------------------|:----------------------------------------------------|
|                     |                             | Stephen Stamp                                       |
|                     |                             | Chief Executive Officer and Chief Financial Officer |

Exhibit 99.1

<div align='center'>Biodexa Pharmaceuticals PLC

(“Biodexa” or the “Company”)

Results of Annual General Meeting</div>

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage
biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces
that at its Annual General Meeting held yesterday, all resolutions put to the Company’s shareholders were duly passed.

The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website athttps://biodexapharma.com/investors/corporate-governance//#agms.

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical
stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The
Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non Muscle Invasive
Bladder Cancer: tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive
rare/orphan brain cancer indications.

eRapa is a proprietary oral tablet formulation of rapamycin,
also known as sirolimus. Rapamycin is an mTOR (ammalian arget